文献速递妇产影像介入US

经皮微波消融治疗子宫后壁腺肌症的有效性与安全性

Efficacy and safety of percutaneous microwave ablation for adenomyosis in the posterior uterine wall.
PubMed 文献 · Br J Radiol · 2023-04-17

回顾性纳入36例子宫后壁症状性腺肌症患者,20例因后倾/后屈子宫无理想经腹穿刺路径接受PMWA联合Yu's子宫悬吊术(组1),16例仅行PMWA(组2)。平均NPV比率为90.2±18.3%,痛经和月经过多完全缓解率分别为81.3%和69.6%,复发率11.1%,无重大并发症。两组各项指标均无显著差异(p>0.05)。

要点

  • PMWA治疗子宫后壁腺肌症平均NPV比率达90.2±18.3%,痛经完全缓解率81.3%。
  • 后倾/后屈子宫无经腹穿刺路径时,可联合Yu's子宫悬吊术扩大PMWA适应症。
  • 无重大并发症,轻微并发症包括下腹痛55.6%、发热41.7%、阴道排液47.2%、恶心呕吐19.4%。

关键影像表现/征象

  • 36例平均NPV比率为90.2±18.3%。
  • 痛经完全缓解率81.3%(26/32),月经过多完全缓解率69.6%(16/23)。
  • 复发率11.1%(4/36),无重大并发症。
  • 轻微并发症发生率:下腹痛55.6%、发热41.7%、阴道排液47.2%、恶心和/或呕吐19.4%。
  • 亚组分析显示两组NPV比率中位数、痛经和月经过多缓解率、临床评分变化、复发率及经济成本均无显著差异(均p>0.05)。

临床应用与阅片要点

  • 超声引导PMWA可用于子宫后壁腺肌症,NPV比率高且症状缓解明显。
  • 后倾或后屈子宫经腹穿刺路径不佳时,可考虑联合Yu's子宫悬吊术。
  • 术后常见轻微并发症如下腹痛、发热、阴道排液和恶心呕吐,需注意识别和处理。

局限性

  • 回顾性研究,样本量较小(36例),非随机分组。
  • 单中心研究,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the efficacy and safety of percutaneous microwave ablation (PMWA) for treating adenomyosis in the posterior uterine wall.

METHODS: Thirty-six patients with symptomatic adenomyosis in the posterior uterine wall who had been subjected to PMWA were retrospectively enrolled in this study. 20 patients who had no ideal transabdominal puncture path due to the retroverted or retroflexed uterine position were treated with PMWA combined with Yu's uteropexy (Group 1). The other 16 patients were treated with PMWA only (Group 2). The non-perfused volume (NPV) ratio, symptomatic relief rate, recurrence rate, changes in clinical symptom scores, economic cost, and complications were compared.

RESULTS: The mean NPV ratio for the 36 patients was 90.2±18.3%, and the percentage of patients who obtained complete relief of dysmenorrhea and menorrhagia was 81.3% (26/32), and 69.6% (16/23) respectively. The recurrence rate was 11.1% (4/36). No major complication was observed. Minor complications included lower abdominal pain, fever, vaginal discharge, nausea, and/or vomiting after ablation, with incidences of 55.6%, 41.7%, 47.2%, and 19.4% respectively. Subgroup analysis showed no significant difference in the median value of NPV ratio, symptomatic relief rate of dysmenorrhea and menorrhagia, changes in clinical symptom scores, recurrence rate and economic cost between the two groups (all p > 0.05).

CONCLUSION: PMWA is an effective and safe treatment for adenomyosis in the posterior uterine wall.

ADVANCES IN KNOWLEDGE: This study focused on the ultrasound-guided PMWA treatment for adenomyosis in the posterior uterine wall. Yu's uteropexy, a new ancillary technique allowing safe PMWA for deep posterior uterine wall lesions in retroverted uterus, expanded the indications of PMWA for symptomatic adenomyosis.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Zhang, Yu, Li, et al. Efficacy and safety of percutaneous microwave ablation for adenomyosis in the posterior uterine wall. Br J Radiol. 2023. PMID: 37017557. doi:10.1259/bjr.20211301

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。